Relation of HIV-I in bronchoalveolar lavage cells to abnormalities of lung function and to the presence of *Pneumocystis* pneumonia in HIV-I seropositive patients

John R Clarke, Ian K Taylor, Judith Fleming, John D Williamson, David M Mitchell

Abstract

*Background*—HIV is present in bronchoalveolar lavage cells of some but not all HIV seropositive patients. Abnormalities of lung function have been described in such patients in the absence of clinically overt pneumonia or other respiratory infections. It is possible that the presence of HIV in alveolar macrophages could account for these abnormalities. It is also possible that the presence of HIV in alveolar macrophages contributes to immunosuppression and an increased incidence of opportunistic infections.

*Methods*—This was a prospective study of 157 HIV seropositive patients requiring diagnostic bronchoscopy for investigation of new respiratory symptoms, chest radiograph abnormality, or pneumonic illness. Presence of HIV in bronchoalveolar lavage cells obtained at diagnostic bronchoscopy was determined by polymerase chain reaction to detect proviral DNA and in vitro cocultivation to detect productive virus infection. With these two techniques the presence or absence of HIV in bronchoalveolar lavage was compared with the presence of abnormalities of lung function or presence of *Pneumocystis* pneumonia.

*Results*—HIV was detected in bronchoalveolar lavage cells in 65% of patients by means of the polymerase chain reaction and 59% with cocultivation. With both methods of detection there was no association between the presence or absence of HIV and the presence of *Pneumocystis* pneumonia; nor was there a relation between the presence of HIV and abnormalities of lung function.

*Conclusion*—The presence of HIV in bronchoalveolar lavage cells does not predispose to an increased incidence of *Pneumocystis* pneumonia; nor does it contribute to abnormalities of lung function.

(Thorax 1993;48:1222–1226)
**Patients and methods**

One hundred and fifty seven consecutive HIV seropositive patients undergoing investigation for new respiratory symptoms (recent onset of cough, or breathlessness, or both), new abnormal chest radiograph findings, or pneumonic illness were prospectively studied. One hundred and fifty three were homosexual or bisexual men, four were women; intravenous drug users were excluded from the study. Between 48 and 72 hours before bronchoscopy all patients had the following lung function tests performed after a period of rest: forced expiratory volume in one second (FEV$_1$), forced vital capacity (FVC) with a dry bells spirometer (Vitalograph Ltd, Buckingham, UK), peak expiratory flow (PEF), transfer factor for carbon monoxide (TLC/CO), and diffusion coefficient (KCO) with the single breath helium dilution method (PK Morgan, Gillingham, Kent, UK). Six patients were either too unwell for pulmonary function testing or the tests were not obtained before the study. Results were expressed as a percentage of predicted normal value. All values were corrected for haemoglobin. Corrections for ethnicity were made where appropriate. At routine fibroptic bronchoscopy performed by an experienced bronchoscopist, bronchoalveolar lavage (BAL) with warmed sterile saline was performed in the right middle lobe for diagnostic cytology and for bacteriological and virological culture. A 25 ml aliquot of BAL was obtained for this study and a 20 ml sample of venous blood was taken at the time of bronchoscopy for comparison with BAL cells. *Pneumocystis* pneumonia was diagnosed on the basis of finding the cyst form of *Pneumocystis carinii* in the Grocott stained sediment of BAL samples or the trophozoite form with Giemsa stain. Local ethics committee approval for the study was obtained, and informed consent was obtained from each patient before the study.

For HIV-I detection and viral isolation (with full standard laboratory precautions in a category 3 facility) the BAL sample was centrifuged at 1500 g (MSE Mistral 1000, Leicester, UK) for 15 minutes to deposit cells. The supernatant liquid was discarded and the cells were washed twice in serum free RPMI-1640 cell culture medium (Flow Laboratories, Rickmansworth, UK) containing fungizone (50 μg/ml). Cells in BAL fluid were then counted and viability (>98%) was checked with trypan blue. Two million cells were then seeded into each well of six well cell culture plates (Sterilin, Hounslow, UK). The cells were stimulated with 1 μg/ml phytohaemagglutinin (PHA-L) and 500 units/ml recombinant interleukin-2 (MRC AIDS Directed Programme Repository, Potters Bar, Hertfordshire, UK). To each culture 2 × 10$^6$ PHA stimulated cord blood leucocytes were added with a further 5 ml RPMI-1640 medium (Flow Laboratories, Rickmansworth, UK) containing 10% fetal calf serum, 1-68 g/l sodium bicarbonate, 100 μg/ml penicillin, 100 μg/ml streptomycin, and 50 μg/ml nystatin. Peripheral blood leucocytes were prepared from each patient by Ficoll-Hypaque centripagation and separation, and treated in the same manner as BAL cells.

The polymerase chain reaction analysis for the detection of HIV-I proviral DNA was carried out on samples from all 157 patients, with oligonucleotide primers to the gag and reverse transcriptase regions of the HIV-I genome as previously described. A rigorous technique was employed to avoid cross contamination and in each experiment DNA amplification by polymerase chain reaction was run as a negative control. For polymerase chain reaction analysis, the BAL and peripheral blood leucocyte cell populations were divided into adherent (macrophage or monocyte enriched, 98% of cells were positive for non-specific esterase staining) and non-adherent (macrophage or monocyte depleted) cell fractions by a plastic adherence step of 18 hours in one well of a six well plate. The attempted isolation of HIV by cocultivation for 100 patients in this study was done by culturing patients’ leucocytes from BAL or peripheral blood with cord blood leucocytes. The cultures were incubated in an atmosphere of 5% carbon dioxide for 28 days. On the first day and thereafter twice weekly the cultures were examined microscopically for a cytopathic effect. Two ml of culture supernatant were carefully removed, 1 ml was stored at −20°C for virological examination for p24 antigen and reverse transcriptase assays, and 1 ml was stored in the gaseous phase of liquid nitrogen for further analysis. The p24 antigen enzyme immunoassay and reverse transcriptase assays were undertaken as previously described. Statistical comparisons were made using the χ$^2$ test and Student’s t test.

### Results

Polymerase chain reaction analysis for the detection of HIV-I proviral DNA was carried out on the peripheral blood and BAL cells from all 157 patients and cocultivation analysis for the detection of productive HIV-I virus infection was carried out in 100 of the 157 patients. Table 1 shows the results. HIV-I was detected by the polymerase chain reaction in 149 of 157 (95%) of the non-adherent fraction of peripheral blood containing the CD4+ lymphocyte enriched fraction and in 82 of 157 (52%) of the adherent peripheral blood leucocyte population (monocyte en-

---

**Table 1** HIV proviral DNA detected by the polymerase chain reaction (PCR) and HIV isolated by cocultivation in cells obtained from peripheral blood and bronchoalveolar lavage in HIV-I seropositive patients with respiratory symptoms

<table>
<thead>
<tr>
<th>Peripheral blood leucocytes</th>
<th>Bronchoalveolar lavage</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAD</td>
<td>Ad</td>
</tr>
<tr>
<td>HIV detected by PCR (157 patients)</td>
<td></td>
</tr>
<tr>
<td>149 (95)</td>
<td>82 (52)</td>
</tr>
<tr>
<td>HIV detected by cocultivation* (100 patients)</td>
<td></td>
</tr>
<tr>
<td>52 (52)</td>
<td>59 (59)</td>
</tr>
</tbody>
</table>

NAD—non-adherent cells containing mainly lymphocytes; Ad—adherent cells containing >98% monocytes/macrophages.

*Unseparated cells.

Results are numbers of patients (%).
riched). In eight patients HIV could not be detected by the polymerase chain reaction in the peripheral blood non-adherent cell fraction; five of these patients had been on long term AZT treatment (>three months) and in the remaining three there were no detectable CD4+ lymphocytes in the peripheral blood leucocyte non-adherent cell fraction. HIV-I proviral DNA was detected in 83 out of 157 (53%) of non-adherent BAL cell fractions and in 80 out of 157 (51%) of the purified alveolar macrophage samples. Overall HIV-I proviral DNA was detected in one or other of the BAL cell fractions from 102 out of 157 (65%) patients. With in vitro cocultivation, productive HIV-I infection was shown in peripheral blood leucocytes from 52 of 100 patients and BAL from 59 of 100 patients. Table 2 shows the relation between the detection of HIV-I proviral DNA by the polymerase chain reaction and lung function tests. There was no difference in any lung function test between patients in whom HIV could be detected in BAL and those in whom it could not. Table 3 shows the relation between the isolation of HIV-I by cocultivation from BAL cells and lung function tests. There was no significant difference between any lung function test and the presence or absence of HIV by cocultivation. Table 4 shows the relation between *Pneumocystis* pneumonia and the presence or absence of HIV from both adherent and non-adherent BAL cell fractions as detected by the polymerase chain reaction and also the distribution of HIV in the group of patients whose respiratory illness was not due to *Pneumocystis* pneumonia. Of the 104 patients who did not have *Pneumocystis* pneumonia, 12 had bacterial pneumonia (positive blood or BAL culture), seven had pulmonary tuberculosis, six had pulmonary Kaposi's sarcoma alone without a positive microbial culture, 12 had a positive BAL culture for cytomegalovirus—not thought to be a clinically significant finding as these patients all recovered without specific antiviral treatment, and one patient had adenovirus in BAL. In a further four patients there was dual infection (two cytomegalovirus and bacterial infection; one cytomegalovirus and tuberculosis; one tuberculosis and bacterial infection). In the remaining 62 patients no specific microbial diagnosis was made although BAL and sputum often grew normal commensal bacteria. All these patients responded to broad spectrum antibiotics (not cotrimoxazole) and so were presumed to have had a bacterial or self limiting viral infection. Of the 53 patients with *Pneumocystis* pneumonia, 13 had concomitant bacterial infection and one had tuberculosis and cytomegalovirus. There was no association between the presence of HIV in either cell fraction and the presence of *Pneumocystis* pneumonia, or other respiratory diagnoses. Similarly HIV was isolated by cocultivation from 23 of 36 (64%) patients with *Pneumocystis* pneumonia and from 36 of 64 (56%) patients with other respiratory diagnoses. Again the difference in frequency of HIV isolation between the two groups was not statistically significant. Table 5 shows the mean TLco expressed as a percentage of normal for patients with and without *Pneumocystis* pneumonia and with and without PCP.

### Table 2. Relation between detection of HIV-I proviral DNA by the polymerase chain reaction in either adherent or non-adherent BAL cell fractions and lung function tests

<table>
<thead>
<tr>
<th></th>
<th>HIV detected (n = 102)</th>
<th>HIV not detected (n = 55)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FEV₁</td>
<td></td>
</tr>
<tr>
<td></td>
<td>86-6 (28-7) NS</td>
<td>80-2 (25-2)</td>
</tr>
<tr>
<td></td>
<td>FVC</td>
<td>78-0 (24-5) NS</td>
</tr>
<tr>
<td></td>
<td>TLco</td>
<td>48-7 (17-6) NS</td>
</tr>
<tr>
<td></td>
<td>KCO</td>
<td>74-9 (16-2) NS</td>
</tr>
</tbody>
</table>

Values are mean (SD) % of predicted value.

### Table 3. Relation between the isolation of HIV-I by cocultivation from BAL cells and lung function tests

<table>
<thead>
<tr>
<th></th>
<th>HIV isolated (n = 59)</th>
<th>HIV not isolated (n = 41)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FEV₁</td>
<td></td>
</tr>
<tr>
<td></td>
<td>84-1 (33-9) NS</td>
<td>79-4 (24-7)</td>
</tr>
<tr>
<td></td>
<td>FVC</td>
<td>82-4 (27-1) NS</td>
</tr>
<tr>
<td></td>
<td>TLco</td>
<td>46-3 (19-9) NS</td>
</tr>
<tr>
<td></td>
<td>KCO</td>
<td>73-7 (11-4) NS</td>
</tr>
</tbody>
</table>

Values are mean (SD) % of predicted value.

### Table 4. Numbers of patients in whom HIV was or was not detected by the polymerase chain reaction in non-adherent and adherent cell fractions of BAL from patients with *Pneumocystis* pneumonia (PCP) (n = 53) and patients without PCP (n = 104)

<table>
<thead>
<tr>
<th></th>
<th>NAd</th>
<th>Ad</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV detected</td>
<td>HIV not detected</td>
</tr>
<tr>
<td>Patients with PCP (n = 53)</td>
<td>31</td>
<td>22</td>
</tr>
<tr>
<td>Patients without PCP (n = 104)</td>
<td>52</td>
<td>52</td>
</tr>
</tbody>
</table>

NAd—Non-adherent cells; Ad—adherent cells.

There was no statistically significant relation between presence or absence of HIV and PCP or non-PCP pneumonia.

### Table 5. Mean (SD) TLco expressed as percentage of normal for patients with and without *Pneumocystis* pneumonia (PCP) where HIV was or was not detected by the polymerase chain reaction

<table>
<thead>
<tr>
<th></th>
<th>NAd</th>
<th>Ad</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV detected</td>
<td>HIV not detected</td>
</tr>
<tr>
<td>PCP</td>
<td>41-9 (16-0) NS</td>
<td>41-8 (13-8)</td>
</tr>
<tr>
<td>Non-PCP</td>
<td>57-0 (18-7) NS</td>
<td>61-3 (10-4)</td>
</tr>
</tbody>
</table>

NAd and Ad as defined in table 4.
out HIV detected in cell fractions of BAL by the polymerase chain reaction. The presence of HIV had no additional effect on TLCo in any patient group.

Discussion

In the present study we have confirmed and extended the findings that HIV-I can be detected in bronchoalveolar lavage cell populations of some but not all HIV seropositive patients and that the presence of HIV-I can be shown both by the polymerase chain reaction to detect proviral DNA and by cocultivation in vitro to demonstrate productive viral infection.\(^8\)\(^9\) We next asked two questions: does the presence or absence of HIV-I in bronchoalveolar lavage cells have any influence on abnormalities of pulmonary function or does the presence of the virus predispose to opportunistic lung infections, in particular Pneumocystis pneumonia? We first used the polymerase chain reaction to detect proviral DNA and found that 65% of our patients had HIV detectable in one or other of their BAL cell fractions. We were thus able to look at our two patient groups where HIV was present and absent to see if presence of the virus had any effect on pulmonary function tests, in particular TLCo, and the presence of Pneumocystis pneumonia. We found that it did not. As the polymerase chain reaction detects proviral DNA, which may represent a latent virus infection or defective viral infection incapable of replication and therefore unable to have a pathogenic effect, we next looked for the ability of HIV to be cocultured in vitro from BAL cells. We found that in 59% of our patients HIV could be recovered by culture and again we were able to look at two patient groups, where HIV was present and absent, and could see no effect both on pulmonary function tests, in particular TLCo, and the presence or absence of Pneumocystis pneumonia. Again we found that the presence of HIV did not influence pulmonary function tests or the presence of Pneumocystis pneumonia. We therefore conclude that the presence of HIV-I in BAL cells does not make an additional contribution to immunosuppression to the extent that this is manifest by an increased incidence of Pneumocystis pneumonia or other respiratory illness. We also conclude that the presence of HIV-I does not make an additional contribution to the abnormalities of lung function described previously.\(^8\)

On the basis of this study it seems that the mere presence of the virus does not affect either of these features. Others have reported, however, that after seroconversion, HIV-I specific CD8+ cytotoxic lymphocytes (CTLs) appear in the lung and that this is related to the non-specific alveolitis recorded in HIV-I seropositive patients.\(^6\)\(^7\) As well as the presence of HIV in the lung the presence of CTLs may also be required for pathological changes that could account for the abnormal lung function tests described in these patients.\(^8\) It seems that HIV-I specific CTLs can initiate inflammatory changes in the lung,\(^17\) and CD8+, D44+ CTLs can be detected in BAL in the absence of opportunistic lung infections or tumours in HIV-I seropositive patients. In one study non-specific interstitial pneumonitis was seen in 38% of AIDS patients\(^18\) and accounted for 32% of episodes of clinical pneumonitis in HIV-I seropositive patients. Further investigation by these workers showed that after transbronchial biopsy 11 of 23 (48%) patients had histological evidence of chronic interstitial pneumonitis.\(^18\) Infiltration of lymphocytes in BAL fluid has been linked to the presence of HLA-DR5 and seems to be a genetically determined host response to HIV.\(^20\) A clear causal link between the presence of CTLs specific for HIV and the generation of lung disease and ensuing abnormalities of lung function or pulmonary opportunistic infections remains to be established. If, in due course, it is, this would suggest that the host response to HIV in the lung may be important in pathogenesis as the present study shows that the mere presence of HIV in BAL fluid neither contributes to abnormalities of lung function nor predisposes to pulmonary opportunistic infections.

We thank Siobhan Crossan for typing the manuscript. This work was supported by the Medical Research Council AIDS Directed Programme.

Adventitia

To Egypt—with my defibrillator

Prologue

A wealthy Sheikh decides to invest in a major building project in his native city but, instead of using his own money, wishes to secure a large loan from a major Arab bank. He hires, as his agent and contact man, a shrewd wealthy Arab businessman whom we shall call X.

In May 1977 X was admitted to our Coronary Care Unit with an inferior myocardial infarct (Day 1). Within 30 minutes he had a cardiac arrest due to ventricular fibrillation from which he was promptly and successfully resuscitated by my junior staff. His subsequent medical progress was uneventful, but I was then informed that he was returning to Cairo by Day 11 in order to conclude a £20 million business deal. My initial reaction was to say "no chance", until told that the patient would be accompanied by his personal medical attendant who would take full responsibility for his management. Suitable arrangements would be made for boarding and reception at the other end and, of course, the flight would be first class. Much to their chagrin, I informed my junior staff that this was a job for men not boys; I assembled a bag containing the wherewithal for intubation, various drugs, and a small portable, battery operated, defibrillator. On Day 9 we were ready to depart.

The scene changes to the exotic surroundings of a plush hotel near Heathrow. A meeting had been arranged with the other UK based partners of which I only learned on the way to London and tried to dissuade him from attending. My worst fears were then realised. Far from being amicable, the meeting became increasingly acrimonious over the amount of commission to be paid to each participant. No agreement could be reached and I became concerned about the effects of catecholamine release on my patient’s (and my own) myocardium. The main participants were eventually separated by a lawyer and we retired to eat and rest. The following morning we departed for Cairo—an uneventful but truly luxurious flight—and arrived to a hero’s welcome. My patient was engulfed by various members of his large family and greeted effusively. We then embarked in a fleet of limousines for the centre of Cairo—a hair-raising and high speed experience which anyone familiar with travelling in that city will know. With immense relief I delivered him safe, sound and asymptomatic to the Cardiac Institute and his local cardiologist.

This should have been the end of the story, but X was keen for me to stay on for a time and I accompanied him the next day (Day 11) to a major bank where he had to negotiate exhaustively, but eventually successfully, with the manager over the massive loan. A pleasant interlude sightseeing was followed by an emergency call in the early hours of the morning to a nursing home where he was now in mild left ventricular failure; I administered morphine intramuscularly and frusemide intravenously and he recovered. He was then well enough to insist that I visited some of the marvels of ancient Thebes, and I spent an unforgettable two days visiting the Temples of Karnak and the valleys and tombs of the Kings and Queens, flying home on Day 17.

It was perhaps the strange combination of medical hazard and a glimpse into the turbulent world of high finance which made this trip seem more like a month than the actual week it spanned. On my return colleagues were singularly unimpressed by my trip to Cairo; they thought I had been visiting Caeruau, a small mining village near Bridgend!

Epiilogue

Sadly the building project was never completed. X continued to smoke heavily and to work 12 hours a day. Some years later he had coronary artery bypass grafting performed in London. We keep in touch, indeed he was in London only recently with a sick grandchild. He is well.

GUY CHAPPELL

This column is now open to allcomers for suitable contributions (maximum 600 words). We would like to keep this column running.—SGS
Relation of HIV-I in bronchoalveolar lavage cells to abnormalities of lung function and to the presence of Pneumocystis pneumonia in HIV-I seropositive patients.

J R Clarke, I K Taylor, J Fleming, J D Williamson and D M Mitchell

Thorax 1993 48: 1222-1226
doi: 10.1136/thx.48.12.1222

Updated information and services can be found at:
http://thorax.bmj.com/content/48/12/1222

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/